Latest Share Purchase Plan News

Turaco Gold has reported a significant 40% increase in its Afema Project gold resource to 3.55 million ounces, alongside promising high-grade drilling results and a robust $60 million capital raise to fund ongoing development.

Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.

FireFly Metals reports exceptional drilling results at its Green Bay Copper-Gold Project, extending mineralisation well beyond current resources. Backed by a substantial A$145 million capital raise, the company is poised for a resource update and advancing mining studies.

Bio-Gene Technology Limited has secured $2.45 million to fund critical safety studies and scale-up production of its novel insecticides Flavocide and Qcide, positioning the company for upcoming regulatory approvals and commercial partnerships.

Orion Minerals reported significant cash outflows in its June 2025 quarter, with liquidity stretched and financing facilities nearly maxed out. The company is pursuing a $5.8 million capital raising to support ongoing operations following recent feasibility study completions.

Orion Minerals is advancing its Prieska Copper Zinc Mine towards production, targeting first concentrate by Christmas 2026, supported by a recent $5.8 million capital raise and ongoing project optimisation.

Latrobe Magnesium secures EPA licence extension and prepares to start magnesium oxide production in August, while pursuing a significant legal counterclaim and advancing commercial plant plans.

Arizona Lithium has secured regulatory approval for Phase 1 production at its Prairie Lithium Project in Saskatchewan and raised $4.25 million through an oversubscribed share purchase plan, marking key milestones toward commercial lithium extraction.

Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.

BluGlass Limited has secured its first order from the Indian Department of Defence and reported a significant 16% improvement in visible laser efficiency, alongside raising $7.6 million to support growth.

Scalare Partners has forged a strategic collaboration with Silicon Catalyst, a leading US semiconductor accelerator, while advancing its acquisition of Tank Stream Labs, a premier Australian tech coworking provider. These moves position Scalare at the forefront of deep tech support and infrastructure expansion.

S2 Resources advances exploration across multiple Australian projects with promising gold and base metal anomalies, while bolstering its balance sheet through a successful A$3.5 million capital raise.